E-Mail Newsletter (MLL News)

Our newsletter is an offer of MLL Münchner Leukämielabor GmbH, Max-Lebsche-Platz 31, 81377 Munich (“MLL,” “we”) and contains information about our products and services, research results, events and other news relevant to the company and to the discipline, especially regarding diagnostics and subsequent therapy for leukemia and lymphoma. For you to subscribe, we need the e-mail address that you want us to send the newsletter to. We may use optional information to personalize how the addressee is addressed.
To continuously improve the quality of our newsletter and its contents, we conduct a pseudonymized analysis of the opening rate of the newsletter and information on calling up specific articles. You can find detailed information on how personal data is processed in connection with our newsletter in our Data protection information section.


By clicking on the “Subscribe to the newsletter” button, I consent to allow MLL to use the e-mail address and optional information provided by me for sending the newsletter and for addressing me personally.

 

Newsletter registration

You have the right to withdraw your consent at any time. Withdrawing your consent does not affect the lawfulness of the processing that took place based on your consent up until the time of withdrawal. One way you can withdraw your consent is by using the withdrawal function contained in every newsletter. Alternatively, you can declare that you are withdrawing your consent by sending an e-mail to or by mailing a letter to MLL Münchner Leukämielabor GmbH, Max-Lebsche-Platz 31, 81377 Munich.

MLL Magazine

Stay up to date

Here you will find all MLL News as well as scientific contributions to leukemia diagnostics and research.

to the MLL Magazine

Current Articles

  • Prof. Dr. med. Dr. phil. Torsten Haferlach
    from 16.12.2020
    MLL News
    The MLL says Thank You

    This very different year is coming to an end. We all had to realize, professionally and privately, that plans and goals are only relative. Furthermore, it became clear how centrally "medicine" can influence our daily lives and actions. We as MLL would like to look back and forward and thank you for the trust you have placed in us and for your cooperation.

    Post review
    Read article
  • PD Dr. med. Gregor Hörmann, PhD
    from 16.12.2020
    Diagnostics
    Molecular genetics in mastocytosis and hypereosinophilia

    Advanced molecular genetic testing is gaining ground in the diagnosis of mast cell diseases and hypereosinophilia. In addition to the typical mastocytosis-driver mutation KIT D816 as well as PDGFRA, PDGFRB, FGFR1, and PCM1-JAK2 rearrangements, the MLL uses advanced Next-Generation Sequencing (NGS) mutation analysis to inform the diagnosis and prognostic stratification of these diseases. These NGS gene panels are continuously updated to reflect the latest advances in scientific understanding.

    Post review
    Read article
  • Dr. med. Adriane Koppelle
    from 16.12.2020
    Diagnostics
    Advances in the targeted therapy of hematological neoplasm

    In recent years, research into the underlying pathogenetic mechanisms of hematologic neoplasms has led to remarkable advances in our understanding of these diseases. Cytogenetic and molecular aberrations are the most important factors in determining response to chemotherapy and are increasingly also therapeutic targets. We would first like to provide an overview of novel therapies for AML whose target genes can be sequenced in MLL.

    Post review
    Read article
  • Sarah Kurz
    from 11.12.2020
    MLL News
    The MLL Munich Leukemia Laboratory belongs to BAVARIA'S BEST 50

    It is now official: As of this year, the MLL Munich Leukemia Laboratory is one of the 50 fastest-growing medium-sized companies in Bavaria. In recent years, the company has been able to increase its sales and the number of its employees at an above-average rate. In recognition of this achievement, MLL was awarded the BAVARIA'S BEST 50 prize by the Bavarian State Ministry of Economic Affairs, Regional Development and Energy (STMWI) and the Deputy Bavarian Prime Minister Hubert Aiwanger.

    Post review
    Read article

Contact

Sarah Kurz

MLL Münchner Leukämielabor GmbH
Max-Lebsche-Platz 31
81377 München

T: +49 (0)89 99017-547

Getting here